Kainova Therapeutics Secures $32 CAD in Series B Funding

There is a moment in every serious company’s life where time stops playing defense and finally runs your route. The Greeks had a word for it. Kairos. The exact right moment. Kainova Therapeutics chose that name for a reason, and this week they proved they understand timing better than most rooms pretending to run biotech.

$22.4M, Series B first close, led by Investissement Québec, with CTI Life Sciences, Panacea Venture, 3B Future Health Fund, Seventure Partners, Viva BioInnovator, Turenne Capital, Schroders Capital, adMare BioInnovations, and Seido Capital leaning back in. Capital does not move like this unless conviction already walked in ahead of it. This was not momentum. This was recognition.

Kainova Therapeutics is not guessing at GPCRs. They are operating inside them. bioSens-All® is not branding gloss, it is a working engine that has already produced a Phase II-ready EP4 antagonist in DT-9081, now carrying lessons learned from the EPRAD Phase I study. It is pushing DT-7012, a CCR8 monoclonal antibody built to selectively deplete immunosuppressive Tregs through ADCC and ADCP, now live in the DOMISOL Phase I/II trial. It is setting up DT-9046, a PAR2 biased negative allosteric modulator designed to hold the line in inflammatory disease even when the environment turns hostile. This is signal control in systems where noise kills outcomes.

None of that happens by accident. Sean A. MacDonald, CEO, did not step into the role to admire the architecture. He came to scale it. Stephan Schann, CSO, has been shaping the science since 2008, long before GPCRs became fashionable again. Jean-Marie Cuillerot, CMO, has already taken immunotherapies from pre-IND to global filings elsewhere and knows where the bodies are buried. Stanislas Malmezat, CFO, keeps the math honest while the science gets ambitious. Laurence Terrisse Rulleau, Board Chair, has seen enough cycles to know when a board should press and when it should wait. And yes, this story still traces back to Pascal Neuville and Youssef Bennani, who built the original machine when Domain Therapeutics was still a conviction play.

There is a lesson here for founders watching from the cheap seats. Precision beats volume. Platforms that actually work attract partners like Merck KGaA and Pfizer long before LinkedIn applause shows up. Rebrands matter only when the underlying biology already earned the right to evolve. Capital follows clarity, not noise.